Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pfizer Inc. is conducting a clinical trial titled A Phase 1B, Open-Label Study of Elranatamab in Combination with Carfilzomib Plus Dexamethasone and Elranatamab in Combination with PF-07901801 in Participants with Relapsed Refractory Multiple Myeloma. The study aims to evaluate the safety and tolerability of elranatamab in combination with other drugs for treating relapsed refractory multiple myeloma, a significant concern in cancer treatment.
The study tests two main interventions: elranatamab combined with carfilzomib and dexamethasone, and elranatamab combined with maplirpacept. Elranatamab is a BCMA-CD3 bispecific antibody, carfilzomib is a proteasome inhibitor, and maplirpacept is a CD47-SIRP alpha-directed drug. These combinations are intended to improve treatment outcomes for multiple myeloma patients.
This interventional study is randomized and follows a sequential intervention model with no masking, focusing primarily on treatment. It is designed to identify optimal dosing and assess the safety of the drug combinations over approximately two years.
The study began on December 14, 2022, and is currently recruiting participants. The primary completion date is yet to be determined, with the last update submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
The study’s outcome could significantly impact Pfizer’s stock performance and investor sentiment, especially if the results demonstrate enhanced efficacy and safety. This development is particularly relevant given the competitive landscape in oncology, where advancements can lead to substantial market shifts.
The study is ongoing, with further details available on the ClinicalTrials portal.